GlobeNewswire

Zelluna ASA: Disclosure of large shareholding
04/11/2025
Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement [...]
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
04/11/2025
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolio C3 glomerulopathy (C3G) studies add to body of [...]
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
04/11/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion
04/11/2025
November 4, 2025 Q3 2025 Group Highlights Comparable order intake growth 8% Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable sales Income from operations was EUR 330 million Adjusted EBITA [...]
Zelluna ASA – Ex. date
04/11/2025
The shares in Zelluna ASA will from today, 4 November 2025, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 3 November 2025. This information is published in [...]
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
04/11/2025
Immune response successfully improved with second generation vaccine candidate Saint-Herblain (France), November 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced [...]
Valneva annonce des résultats positifs de Phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika
04/11/2025
Réponse immunitaire améliorée avec le candidat vaccin de deuxième génération Saint-Herblain (France), le 4 novembre 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé [...]
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
04/11/2025
Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids Significantly lower [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum